TY - JOUR
T1 - Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference
AU - Gotlib, Jason
AU - George, Tracy I.
AU - Carter, Melody C.
AU - Austen, K. Frank
AU - Bochner, Bruce
AU - Dwyer, Daniel F.
AU - Lyons, Jonathan J.
AU - Hamilton, Matthew J.
AU - Butterfield, Joseph
AU - Bonadonna, Patrizia
AU - Weiler, Catherine
AU - Galli, Stephen J.
AU - Schwartz, Lawrence B.
AU - Elberink, Hanneke Oude
AU - Maitland, Anne
AU - Theoharides, Theoharis
AU - Ustun, Celalettin
AU - Horny, Hans Peter
AU - Orfao, Alberto
AU - Deininger, Michael
AU - Radia, Deepti
AU - Jawhar, Mohamad
AU - Kluin-Nelemans, Hanneke
AU - Metcalfe, Dean D.
AU - Arock, Michel
AU - Sperr, Wolfgang R.
AU - Valent, Peter
AU - Castells, Mariana
AU - Akin, Cem
N1 - Publisher Copyright:
© 2021 American Academy of Allergy, Asthma & Immunology
PY - 2021/6
Y1 - 2021/6
N2 - The American Initiative in Mast Cell Diseases (AIM) held its inaugural investigator conference at Stanford University School of Medicine in May 2019. The overarching goal of this meeting was to establish a Pan-American organization of physicians and scientists with multidisciplinary expertise in mast cell disease. To serve this unmet need, AIM envisions a network where basic, translational, and clinical researchers could establish collaborations with both academia and biopharma to support the development of new diagnostic methods, enhanced understanding of the biology of mast cells in human health and disease, and the testing of novel therapies. In these AIM proceedings, we highlight selected topics relevant to mast cell biology and provide updates regarding the recently described hereditary alpha-tryptasemia. In addition, we discuss the evaluation and treatment of mast cell activation (syndromes), allergy and anaphylaxis in mast cell disorders, and the clinical and biologic heterogeneity of the more indolent forms of mastocytosis. Because mast cell disorders are relatively rare, AIM hopes to achieve a coordination of scientific efforts not only in the Americas but also in Europe by collaborating with the well-established European Competence Network on Mastocytosis.
AB - The American Initiative in Mast Cell Diseases (AIM) held its inaugural investigator conference at Stanford University School of Medicine in May 2019. The overarching goal of this meeting was to establish a Pan-American organization of physicians and scientists with multidisciplinary expertise in mast cell disease. To serve this unmet need, AIM envisions a network where basic, translational, and clinical researchers could establish collaborations with both academia and biopharma to support the development of new diagnostic methods, enhanced understanding of the biology of mast cells in human health and disease, and the testing of novel therapies. In these AIM proceedings, we highlight selected topics relevant to mast cell biology and provide updates regarding the recently described hereditary alpha-tryptasemia. In addition, we discuss the evaluation and treatment of mast cell activation (syndromes), allergy and anaphylaxis in mast cell disorders, and the clinical and biologic heterogeneity of the more indolent forms of mastocytosis. Because mast cell disorders are relatively rare, AIM hopes to achieve a coordination of scientific efforts not only in the Americas but also in Europe by collaborating with the well-established European Competence Network on Mastocytosis.
KW - American Initiative in Mast Cell Diseases (AIM)
KW - European Competence Network on Mastocytosis (ECNM)
KW - Systemic mastocytosis
KW - anaphylaxis
KW - hereditary alpha-tryptasemia
KW - mast cell activation syndrome
KW - siglec-8
UR - http://www.scopus.com/inward/record.url?scp=85104757942&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2021.03.008
DO - 10.1016/j.jaci.2021.03.008
M3 - Article
C2 - 33745886
AN - SCOPUS:85104757942
SN - 0091-6749
VL - 147
SP - 2043
EP - 2052
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 6
ER -